Cargando…
HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness
SIMPLE SUMMARY: Breast cancer (BC) is not a single disease, but a group of different tumors, and altered HER2 expression defines a particularly aggressive subtype. Although HER2 pharmacological inhibition has dramatically improved the prognosis of HER2-positive BC patients, there is still an urgent...
Autores principales: | Pupa, Serenella M., Ligorio, Francesca, Cancila, Valeria, Franceschini, Alma, Tripodo, Claudio, Vernieri, Claudio, Castagnoli, Lorenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507865/ https://www.ncbi.nlm.nih.gov/pubmed/34638263 http://dx.doi.org/10.3390/cancers13194778 |
Ejemplares similares
-
Intratumor lactate levels reflect HER2 addiction status in HER2‐positive breast cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2018) -
The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
por: Castagnoli, Lorenzo, et al.
Publicado: (2019) -
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients
por: Ligorio, Francesca, et al.
Publicado: (2021) -
Pathobiological implications of the d16HER2 splice variant for stemness and
aggressiveness of HER2-positive breast cancer
por: Castagnoli, L, et al.
Publicado: (2017) -
Inhibition of the Wnt Signalling Pathway: An Avenue to Control Breast Cancer Aggressiveness
por: Castagnoli, Lorenzo, et al.
Publicado: (2020)